Condition 1: Genital wart. Condition 2: Cervix dysplasia. Condition 3: vaginal dysplasia. Condition 4: papilloma of cervix. Anogenital (venereal) warts Mild cervical dysplasia Mild vaginal dysplasia Other benign neoplasms of uterus
Conditions
Interventions
Intervention 1: Patients are treated with 60 Myrtus vaginal suppositories one every night except during menstruation period in the intervention group . Disease status will be reviewed at the beginnin
Treatment - Drugs
Placebo
Patients are treated with 60 Myrtus vaginal suppositories one every night except during menstruation period in the intervention group . Disease status will be reviewed at the beginning and the end of
Patients are treated with 60 placebo vaginal suppositories one every night except during menstruation period in the control group. Disease status will be reviewed at the beginning and the end of the s
Sponsors
Vice Chancellor for Research and Technology Mashhad University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Female patient with vaginal or cervical wart; age between 18 to 50 years Exclusion criteria: patient with Candida, trichomona and other infections vaginitis or cervicitis; patients with recognized immunodeficiency or autoimmune disease; HIV positive patients; Long-term use of corticosteroids or immunosuppressive; smoking; pregnancy; those who had CIN2 and CIN3 in cervix biopsy; Lack of satisfaction in every stage of the study
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HPV virus. Timepoint: Baseline, the end of the study. Method of measurement: HPV-PCR test.;Lesion size. Timepoint: Baseline,the end of the study. Method of measurement: Colposcopy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical symptom. Timepoint: Baseline,end of the first and the second and the third month of the study. Method of measurement: According to the patient's symptoms.;Drug Side Effects. Timepoint: During the study. Method of measurement: According to the patient's symptoms. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Nikakhtar
Faculty of Iranian Traditional Medicine and Complementary of Mashhad University of Medical Sciences
Outcome results
None listed